Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Operating Leases (2019 - 2022)

Aytu Biopharma (AYTU) has disclosed Operating Leases for 3 consecutive years, with $3.5 million as the latest value for Q1 2021.

  • On a quarterly basis, Operating Leases changed N/A to $3.5 million in Q1 2021 year-over-year; TTM through Mar 2021 was $3.5 million, a N/A change, with the full-year FY2020 number at $725000.0, changed N/A from a year prior.
  • Operating Leases was $3.5 million for Q1 2021 at Aytu Biopharma, up from $211056.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.5 million in Q1 2021 to a low of $211056.0 in Q4 2020.
  • A 3-year average of $879970.5 and a median of $303135.0 in 2019 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 24.47% in 2020; the steepest drop was 27.67% in 2020.
  • Aytu Biopharma's Operating Leases stood at $291813.0 in 2019, then dropped by 27.67% to $211056.0 in 2020, then soared by 1558.33% to $3.5 million in 2021.
  • Per Business Quant, the three most recent readings for AYTU's Operating Leases are $3.5 million (Q1 2021), $211056.0 (Q4 2020), and $237497.0 (Q3 2020).